Chirfi Guindo to sell 20,000 Merck (NYSE: MRK) shares under Rule 144

Rhea-AI Filing Summary

The filing shows a planned sale of 20,000 shares of Merck (MRK) common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of 2,368,202.00. Merck had 2,482,022,536 common shares outstanding at the time of this notice.

The seller, identified as Chirfi Guindo, previously sold 20,000 common shares on 02/05/2026 for gross proceeds of 2,437,676.00. The shares to be sold were acquired through restricted stock vesting under a registered plan on several dates between 08/03/2023 and 01/27/2025. By signing, the seller represents they are not aware of undisclosed material adverse information about Merck.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK
Filer CCC
Previous Accession Number Of The Filing
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	20000	2368202.00	2482022536	02/09/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/03/2023	Restricted stock vesting under a registered plan	Issuer			18912	08/03/2023	Not Applicable
Common	10/08/2024	Restricted stock vesting under a registered plan	Issuer			159	10/08/2024	Not Applicable
Common	10/09/2023	Restricted stock vesting under a registered plan	Issuer			143	10/09/2023	Not Applicable
Common	01/10/2025	Restricted stock vesting under a registered plan	Issuer			329	01/10/2025	Not Applicable
Common	01/27/2025	Restricted stock vesting under a registered plan	Issuer			457	01/27/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CHIRFI GUINDO 126 East Lincoln Avenue Rahway NJ 07065	Commn	02/05/2026	20000	2437676.00

144/A: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What insider stock sale does this Form 144/A disclose for MRK?

The filing discloses a planned sale of 20,000 shares of Merck (MRK) common stock on the NYSE. It lists an aggregate market value of 2,368,202.00 and identifies Morgan Stanley Smith Barney LLC as the broker for the contemplated transaction.

Who is selling Merck (MRK) shares and how many were recently sold?

The notice identifies Chirfi Guindo as the seller of Merck (MRK) shares. It reports that 20,000 common shares were sold on 02/05/2026, generating gross proceeds of 2,437,676.00, in addition to the newly planned 20,000-share sale.

How were the Merck (MRK) shares being sold under this Form 144/A acquired?

The Merck (MRK) shares were acquired through restricted stock vesting under a registered plan. Vesting occurred on several dates between 08/03/2023 and 01/27/2025, with specific amounts such as 18,912 shares vesting on 08/03/2023 and smaller lots vesting on later dates.

What is the total number of Merck (MRK) shares outstanding referenced in this filing?

The filing states that Merck (MRK) had 2,482,022,536 common shares outstanding when the notice was prepared. This figure provides context for the relative size of the planned 20,000-share sale, which represents a very small portion of the total shares outstanding.

Which broker will handle the planned Merck (MRK) stock sale under Rule 144?

The planned Merck (MRK) sale will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services. The broker’s address is listed as 1 New York Plaza, 8th Floor, New York, NY 10004, and the shares are expected to be sold on the NYSE.

What representation does the seller make about Merck (MRK) in this Form 144/A?

The seller represents that they do not know any material adverse information about Merck’s current or prospective operations that has not been publicly disclosed. This representation is made as part of signing the notice required under Rule 144.